Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in meta...
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
About this item
Full title
Author / Creator
Forschner, Andrea , Battke, Florian , Hadaschik, Dirk , Schulze, Martin , Weißgraeber, Stephanie , Han, Chung-Ting , Kopp, Maria , Frick, Maximilian , Klumpp, Bernhard , Tietze, Nicola , Amaral, Teresa , Martus, Peter , Sinnberg, Tobias , Eigentler, Thomas , Keim, Ulrike , Garbe, Claus , Döcker, Dennis and Biskup, Saskia
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40-50% of the patients do not respond to these treatments and severe side effects are observed in up to 60%. Therefore, there is a high need to identify reliable biomarkers predicting response. Tumor Mu...
Alternative Titles
Full title
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dcd41e3ba0714b01a699de819cc3958d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dcd41e3ba0714b01a699de819cc3958d
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/s40425-019-0659-0
